Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TNF receptor 2 pathway: drug target for autoimmune diseases.

Literature DB >> 20489699

TNF receptor 2 pathway: drug target for autoimmune diseases.

Abstract

Although drug development has advanced for autoimmune diseases, many current therapies are hampered by adverse effects and the frequent destruction or inactivation of healthy cells in addition to pathological cells. Targeted autoimmune therapies capable of eradicating the rare autoreactive immune cells that are responsible for the attack on the body's own cells are yet to be identified. This Review presents a new emerging approach aimed at selectively destroying autoreactive immune cells by specific activation of tumour necrosis factor receptor 2 (TNFR2), which is found on autoreactive and normal T lymphocytes, with the potential of avoiding or reducing the toxicity observed with existing therapies.

Entities: Disease Gene

Mesh：

Substances：

Year: 2010 PMID： 20489699 DOI： 10.1038/nrd3030

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

145 in total

1. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

2. Psoriasiform eruption induced by infliximab.

Authors: María M Verea; Jesús Del Pozo; M Teresa Yebra-Pimentel; Angeles Porta; Eduardo Fonseca
Journal: Ann Pharmacother Date: 2004-01 Impact factor: 3.154

3. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

Authors: U Chaudhari; P Romano; L D Mulcahy; L T Dooley; D G Baker; A B Gottlieb
Journal: Lancet Date: 2001-06-09 Impact factor: 79.321

4. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes.

Authors: Gabrielle G M Pinkse; Odette H M Tysma; Cees A M Bergen; Michel G D Kester; Ferry Ossendorp; Peter A van Veelen; Bart Keymeulen; Danny Pipeleers; Jan W Drijfhout; Bart O Roep
Journal: Proc Natl Acad Sci U S A Date: 2005-12-09 Impact factor: 11.205

5. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors: Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal: Arthritis Rheum Date: 2006-01

6. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease.

Authors: Arie Levine; Raanan Shamir; Eytan Wine; Batya Weiss; Amir Karban; Ron R Shaoul; Shimon S Reif; Benjamin Yakir; Marcello Friedlander; Yael Kaniel; Esther Leshinsky-Silver
Journal: Am J Gastroenterol Date: 2005-07 Impact factor: 10.864

7. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation.

Authors: Y Ishikawa; K Kashiwase; T Akaza; Y Morishima; H Inoko; T Sasazuki; Y Kodera; T Juji
Journal: Bone Marrow Transplant Date: 2002-04 Impact factor: 5.483

8. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

Authors: Xin Chen; Jeffrey J Subleski; Heather Kopf; O M Zack Howard; Daniela N Männel; Joost J Oppenheim
Journal: J Immunol Date: 2008-05-15 Impact factor: 5.422

9. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration.

Authors: Anita S Chong; Jikun Shen; Jing Tao; Dengping Yin; Andrey Kuznetsov; Manami Hara; Louis H Philipson
Journal: Science Date: 2006-03-24 Impact factor: 47.728

10. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R.

Authors: E Douni; G Kollias
Journal: J Exp Med Date: 1998-10-05 Impact factor: 14.307

176 in total

1. The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand.

Authors: Christine Richter; Sylvia Messerschmidt; Gerlinde Holeiter; Jessica Tepperink; Sylvia Osswald; Andrea Zappe; Marcus Branschädel; Verena Boschert; Derek A Mann; Peter Scheurich; Anja Krippner-Heidenreich
Journal: Mol Cell Biol Date: 2012-04-30 Impact factor: 4.272

10. In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.

Authors: Kateryna Soloviova; Maksym Puliaiev; Mark Haas; Charles S Via
Journal: J Immunol Date: 2013-03-22 Impact factor: 5.422

TNF receptor 2 pathway: drug target for autoimmune diseases.

1. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

2. Psoriasiform eruption induced by infliximab.

3. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

4. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes.

5. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

6. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease.

7. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation.

8. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

9. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration.

10. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R.

1. The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand.

2. Functional intersection of Human Defensin 5 with the TNF receptor pathway.

Review 3. Progranulin: a growth factor, a novel TNFR ligand and a drug target.

4. PGRN induces impaired insulin sensitivity and defective autophagy in hepatic insulin resistance.

5. TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.

Review 6. Vascular smooth muscle cells in cerebral aneurysm pathogenesis.

Review 7. Tumor necrosis factor-α modulates cerebral aneurysm formation and rupture.

Review 8. Inflammatory osteolysis: a conspiracy against bone.

Review 9. The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

10. In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.